May 16, 2007
Urodynamix
Announces NIRS Data to be Presented at 2007 American Urological Association Annual Meeting
VANCOUVER, British Columbia, May 16, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that additional clinical data describing the use of its non-invasive near-infrared spectroscopy (“NIRS”) urodynamics technology has been accepted for presentation at the 102nd American Urological Association (“AUA”) Annual Meeting and Exhibition to be held in Anaheim, California from May 19-24, 2007.
Drs. Lynn Stothers, MD, and Andrew Macnab, MD, from the University of British Columbia, will present clinical study results at AUA 2007. The two abstracts, entitled “Near Infrared Spectroscopy (NIRS) Changes in Oxy and Deoxyhemoglobin During Natural Bladder Filling and Voiding in Normal Volunteers” and “Receiver Operator Curves Describing Near Infrared Spectroscopy (NIRS) Changes During Pressure Flow Studies in Men With Obstruction,” support the use of NIRS as a reliable non-invasive indicator of bladder function in clinical settings.
Based on the clinical data to be presented by Drs. Stothers and Macnab, and on results obtained in previous studies carried out at the UBC Bladder Care Centre and Toronto Western Hospital, Urodynamix believes that its simple, non-invasive NIRS procedure will provide clinically relevant information that will aid in the diagnosis and influence the course of treatment in men with lower urinary tract symptoms (“LUTS”) and male and female patients with urinary incontinence (“UI”).
Urodynamix has exclusive worldwide rights for NIRS applications related to the bladder, including the diagnosis and characterization of UI and LUTS, conditions that affect approximately 60 million people in North America. The Company is developing an integrated NIRS Bladder Monitor for hospital-based urodynamic evaluation and related stand-alone applications for primary care, and expects its products to be available for sale in the US, EU and Canada in the first quarter of 2008.
About AUA 2007
The American Urological Association’s Annual Meeting is the world’s largest meeting of urologic professionals. More than 10,000 urologists and health care professionals and 5,000 exhibitors will be in attendance with over 350 exhibitors showcasing their urological products or services.
About Urodynamix Technologies Ltd.
Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to beneficially affect the diagnosis and treatment of more than 200 million people worldwide.
On behalf of the Board,
“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com
|
